

# Indian Pharma Sector

## comparable company valuation

Figures in Cr.

Company	Market data					Financials			Valuation		
	Share price	Shares outstanding	equity value	net debt	enterprise value	Revenue	EBIT	Net Income	EV/ Revenue	EV/EBIT	P/E
Dr Reddy's Labs	1254.70	83.46	104717.3	4676.60	106933.66	32643.9	7811.2	5725.2	3.3x	13.7x	18.3x
Sun Pharma.Inds.	1672.00	239.93	401163	2362.19	392193.53	52578.44	14677.74	10964.75	7.5x	26.7x	36.6x
Divi's Lab.	6835.00	26.55	181469.3	4.00	177758.25	9360	2918	2191	19.0x	60.9x	82.8x
Cipla	1485.00	80.78	119958.3	438.19	119596.65	27547.62	6713.61	5269.2	4.3x	17.8x	22.8x
Torrent Pharma.	3314.20	33.84	112152.5	3202.32	114775.39	11516.09	2931.26	1911.25	10.0x	39.2x	58.7x
Mankind Pharma	2578.30	41.27	106406.4	8511.45	114363.39	12207.44	2945.74	2011.12	9.4x	38.8x	52.9x
Zydus Lifesci.	979.60	100.62	98567.35	3213.20	98823.75	23241.5	6412.2	4672.6	4.3x	15.4x	21.1x
Lupin	1894.70	45.67	86530.95	5447.77	88836.39	22707.9	4309.87	3306.26	3.9x	20.6x	26.2x
Abbott India	34420.00	2.12	72970.4	196.67	71539.15	6409.15	1898.38	1414.44	11.2x	37.7x	51.6x
Aurobindo Pharma	1124.80	58.59	65902.03	8262.87	65929.41	31723.73	5523.53	3483.57	2.1x	11.9x	18.9x
High									19.0x	60.9x	82.8x
75th percentile									9.8x	38.5x	52.6x
<b>Average</b>									<b>7.5x</b>	<b>28.3x</b>	<b>39.0x</b>
<b>Median</b>									<b>5.9x</b>	<b>23.7x</b>	<b>31.4x</b>
25th Percentile									4.0x	16.0x	21.5x
Low									2.1x	11.9x	18.3x

Dr Reddy' Labs Comparable Valuation						EV/ Revenue	EV/EBIT	P/E
Implied enterprise value						192609.77	184862.23	184328.96
Net debt						4676.60	4676.60	4676.60
Implied market value						187933.17	180185.63	179652.36
Shares outstanding						83.46	83.46	83.46
<b>Implied value per share</b>						<b>2251.78</b>	<b>2158.95</b>	<b>2152.56</b>
						Undervalued	Undervalued	Undervalued

### Footnotes

Prepared by **Veda Vedhya** – For educational use only

Sources: Screener.in (financials & market data), Yahoo Finance (share price validation), Annual Reports (company-level financial disclosures)

Disclaimer: This analysis is for educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.

Valuation results are based on historical data and standard assumptions. Actual market outcomes may differ materially.

Assumptions: Valuation based on trailing twelve-month (TTM) financials; peer selection driven by market capitalization and business similarity